Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S400000, C548S340100, C548S136000
Reexamination Certificate
active
11248491
ABSTRACT:
Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity.
REFERENCES:
patent: 5068247 (1991-11-01), Fujita et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6667025 (2003-12-01), Chiba et al.
Christensen, I.T. et al., “Excitatory Amino Acid Receptor Ligands. Synthesis and Biological Activity of 3-Isoxazolol Amino Acids Structurally Related to Homoibotenic Acid,” J. Med. Chem., 1992, 35, 3512-3519.
Chen et al., “The identification of myriocin-binding proteins,” Chemistry & Biology 1999, vol. 6, No. 4, pp. 221-235.
Clemens et al., “Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective SIP4 receptor agonists,” Bioorganic & Medicinal Chemistry Letters 14 (2004) pp. 4903-4906.
Ding, W. and Yin, X., “Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury,” J. Cell. Mol. Med. vol. 8, No. 4, 2004, pp. 445-454.
Hale et al., “Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720,” Bioorganic & Medicinal Chemistry Letters 14 (2004) pp. 3351-3355.
Hale et al., “Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720,” Bioorganic & Medicinal Chemistry 12 (2004) pp. 4803-4897.
Hanada, K., “Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism,” Biochimica et Biophysica Acta 1632 (2003) pp. 16-30.
Hojjati et al., “Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice,” J. of Biol. Chem. vol. 280, No. 11, Mar. 18, 2005, pp. 10284-10289.
Fujita et al., “Potent Immunosuppressants, 2-Alkyl-2-aminopropane-1,3-diols,” J. Med. Chem., 1996, 39:4451-4459.
Kiuchi et al., “Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols,” J. Med. Chem., 2000, 43:2946-2961.
Kobayashi et al., “Catalytic Asymmetric Synthesis of Antifungal Sphingofungins and Their Biological Activity as Potent Inhibitors of Serine Palmitoyltransferase (SPT),” J. Am. Chem. Soc. 1998, 120:908-919.
Maedler et al., “Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic β-Cell Turnover and Function,” Diabetes, vol. 52, Mar. 2003, pp. 726-733.
Nakamura et al., “Dual Roles of Sphingolipids in Signaling of the Escape from and Onset of Apoptosis in a Mouse Cytotoxic T-cell Line, CTLL-2,” J. of Biol. Chem., vol. 271, No. 3, Jan. 19, 1996, pp. 1255-1257.
Park et al., “Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E-Knockout Mice,” Circulation, Nov. 30, 2004, pp. 3465-3471, DOI: 10.116/01.CIR.0000148370.60535.22.
Schmitz-Peiffer et al., “Ceramide Generation is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate,” J. of Biol. Chem., vol. 274, No. 34, Aug. 20, 1999, pp. 24202-24210.
Seebach et al., “Stereoselective Alkylation at C(alpha) of Serine, Glyceric Acid, Threonine, and Tartaric Acid Involving Heterocyclic Enolates with Exocyclic Double Bonds,” Helvetica Chimica Acta, vol. 70 (1987), pp. 1194-1216.
Seidel et al., “Iron-Catalyzed Cross-Coupling Reactions, A Scalable Synthesis of the Immunosuppressive Agent FTY720,” J. Org. Chem. 2004, 69:3950-3952.
Shimabukuro et al., “Fatty acid-induced β cell apoptosis: A link between obesity and diabetes,” PNAS USA vol. 95, pp. 2498-2502, Mar. 1998.
Shimabukuro et al., “Lipoapoptosis in Beta-cells of Obese Prediabetic fa/fa Rats,” J. of Biol. Chem. vol. 273, No. 49, Dec. 4, 1998, pp. 32487-32490.
Smedes, F., “Determination of total lipid using non-chlorinated solvents,” Analyst, 1999, 124:1711-1718.
Sweet et al., “Systematic screening of potential β-cell imaging agents,” Biochemical and Biophysical Res. Communications 314 (2004) pp. 976-983.
Ayasolla, K. et al., “Inflammatory Mediator and β-Amyloid (25-35)-Induced Ceramide Generation and iNOA Expression are Inhibited by Vitamin E,” Free Radical Biol. & Medicine, vol. 37, No. 3, pp. 325-338, 2004.
Beattie, G.M. et al., “Protection From Cell Death in Cultured Human Fetal Pancreatic Cells,” Cell Transplantation, vol. 9, pp. 431-438, 2000.
Beattie, G.M. et al., “Trehalose: A Cryoprotectant That Enhances Recovery and Preserves Function of Human Pancreatic Islets After Long-Term Storage,” Diabetes 46:519-523(1997).
Bell, D.S.H. and Ovalle, F., “Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes,” Diabetes, Obesity and Metabolism 6:363-366 (2004).
Benjamins, J.A. et al., “Protection of Mature Oligodendrocytes by Inhibitors of Caspases and Calpains,” Neurochemical Res., vol. 28, No. 1, Jan. 2003, pp. 143-152.
Bennett, J.W. and Klich, M., “Mytotoxins,” Clinical Microbiol. Reviews, vol. 16, No. 3, Jul. 2003, pp. 497-516.
Buse, J.B. et al., “The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism 6:133-156 (2004).
Canbay, A. et al., “The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse,” J. of Pharmacological and Experimental Therapeutics 308(3):1191-1196 (2004).
Coroneos, E. et al., “Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades,” Biochem J (1996) 316, pp. 13-17.
Creutzfeldt, W., “The [pre-] history of the incretin concept,” Regulatory Peptides 128:87-91 (2005).
Cutler, R.G. et al., “Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease,” PNAS, vol. 101, No. 7, pp. 2070-2075 (Feb. 17, 2004).
Diani, A.R. et al., “Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes,” Am. J. Physiol.
Durand, P. et al., “A New Efficient Synthesis of the Immunosuppressive Agent FTY-720,” Synthesis, 2000, No. 4, pp. 505-506.
Eitel, K. et al., “Different role of saturated and unsatured fatty acids in β-cell apoptosis,” Biochem. and Biophys. Res. Comm. 299 (2002)853-856.
Esmon, Charles T., “Crosstalk between inflammation and thrombosis,” Maturitas 47 (2004) 305-314.
Filipsson, K. et al., “Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Insulin and Glucagon Secretion in Humans,” J. of Clinical Endocrinology and Metabolism 82(9):3093-3098 (1997).
Frost, R.A. and Lang, C.H., “Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones,” Curr. Op. Clin. Nutrition and Metabolic Care 2005, 8:255-263.
Gavrieli, Y. et al., “Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation,” J. Cell Biol. 119:493-501 (Nov. 1992).
Greene, T. and Wutts, P.G.M.,Protective Groups in Organic Synt
Chu Yong
Forbes Medi-Tech (Research), Inc.
McKane Joseph K.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Compounds and methods for treating insulin resistance and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating insulin resistance and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating insulin resistance and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796827